Interim EQ-5D-5L Value Set for Poland: First Crosswalk Value Set in Central and Eastern Europe

Value in Health Regional Issues

Volumn 4, Issue 1, 2014, Pages 19-23

  Golicki, Dominik ^a   Niewada, Maciej ^a   Hout, Ben van ^b   Janssen, M F ^c   Pickard, A Simon ^d  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

5 level; EQ 5D; Models, statistical; Nonparametric; Quality of life; Questionnaires

Indexed keywords

ALGORITHM; ARTICLE; CROSSWALK ALGORITHM; EUROQOL FIVE DIMENSIONAL; HEALTH STATUS; HUMAN; POLAND; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REFERENCE VALUE; ANXIETY; DEPRESSION; DISEASE SEVERITY; GENERAL HEALTH QUESTIONNAIRE; INTERIM FIVE LEVEL EUROQOL FIVE DIMENSIONAL VALUE SET; INTERIM THREE LEVEL EUROQOL FIVE DIMENSIONAL VALUE SET; MORTALITY; PAIN; PATIENT MOBILITY; POLISH CITIZEN; PREDICTIVE VALUE; QUALITY OF LIFE INDEX; SELF CARE;

EID: 84903831468     PISSN: 22121099     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vhri.2014.06.001     Document Type: Article

References (26)

1. Dakin H. Review of studies mapping from quality of life or clinical measures to EQ-5D: an online database. Health Qual Life Outcomes 2013, 11:151.
2. Herdman M., Gudex C., Lloyd A., et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res 2011, 20:1727-1736.
3. EQ-5D-5L user guide basic information on how to use the EQ-5D-5L instrument. Available from: [Accessed January 4, 2014]. http://www.euroqol.org/fileadmin/user_upload/Documenten/PDF/Folders_Flyers/UserGuide_EQ-5D-5L_v2.0_October_2013.pdf.
4. Janssen M.F., Pickard A.S., Golicki D., et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. Qual Life Res 2013, 22:1717-1727.
5. Devlin N., Krabbe P.M. The development of new research methods for the valuation of EQ-5D-5L. Eur J Health Econ 2013, 14(Suppl. 1):S1-S3.
6. Janssen B.M., Oppe M., Versteegh M.M., et al. Introducing the composite time trade-off: a test of feasibility and face validity. Eur J Health Econ 2013, 14(Suppl. 1). S5-13.
7. Luo N., Li M., Stolk E.A., Devlin N.J. The effects of lead time and visual aids in TTO valuation: a study of the EQ-VT framework. Eur J Health Econ 2013, 14(Suppl. 1):S15-S24.
8. Augustovski F., Rey-Ares L., Irazola V., et al. Lead versus lag-time trade-off variants: does it make any difference?. Eur J Health Econ 2013, 14(Suppl. 1):S25-S31.
9. Ramos-Goñi J.M., Rivero-Arias O., Errea M., et al. Dealing with the health state 'dead' when using discrete choice experiments to obtain values for EQ-5D-5L heath states. Eur J Health Econ 2013, 14(Suppl. 1):S33-S42.
10. Versteegh M.M., Attema A.E., Oppe M., et al. Time to tweak the TTO: results from a comparison of alternative specifications of the TTO. Eur J Health Econ 2013, 14(Suppl. 1):S43-S51.
11. Shah K.K., Lloyd A., Oppe M., Devlin N.J. One-to-one versus group setting for conducting computer-assisted TTO studies: findings from pilot studies in England and the Netherlands. Eur J Health Econ 2013, 14(Suppl. 1):S65-S73.
12. Van Hout B., Janssen M.F., Feng Y.S., Kohlmann T., et al. Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 2012, 15:708-715.
13. EuroQol Group. EQ-5D-5L_Crosswalk_Value_Sets. Available from: [Accessed January 4, 2014]. http://www.euroqol.org/fileadmin/user_upload/Documenten/Excel/Crosswalk_5L/EQ-5D-5L_Crosswalk_Value_Sets.xls.
14. Golicki D., Jakubczyk M., Niewada M., et al. Valuation of EQ-5D health states in Poland: first TTO-based social value set in Central and Eastern Europe. Value Health 2010, 13:289-297.
15. Agency for Health Technology Assessment. Guidelines for conducting health technology assessment (HTA). Version 2.1. 2009. Available from: [Accessed January 4, 2014]. http://www.aotm.gov.pl/assets/files/wytyczne_hta/2009/Guidelines_HTA_eng_MS_29062009.pdf.
16. Niewada M., Polkowska M., Jakubczyk M., et al. What influences recommendations issued by the Agency for Health Technology Assessment in Poland? A glimpse into decision makers' preferences. Value Health Regional 2013, 2:267-272.
17. Golicki D., Niewada M., Jakubczyk M., et al. Self-assessed health status in Poland: EQ-5D findings from the Polish valuation study. Pol Arch Med Wewn 2010, 120:276-281.
18. Zuraw W., Golicki D., Jurecka A., et al. Quality of life among Polish Fabry patients-a cross-sectional study quality of life among Polish Fabry patients. Centr Eur J Med 2011, 6:741-749.
19. Brooks R. EuroQol: the current state of play. Health Policy 1996, 37:53-72. the EuroQol Group.
20. EuroQol Group. EQ-5D-5L. Available from: [Accessed January 7, 2014]. http://www.euroqol.org/eq-5d-products/eq-5d-5l.html.
21. Dolan P. Modeling valuations for EuroQol health states. Med Care 1997, 35:1095-1108.
22. Kaló Z., Bodrogi J., Boncz I., et al. Capacity building for HTA implementation in middle-income countries: the case of Hungary. Value Health Regional 2013, 2:264-266.
23. Boncz I., Kaló Z., Mohamed Ibrahim M.I.B., et al. Further steps in the development of pharmacoeconomics, outcomes research, and health technology assessment in Central and Eastern Europe, Western Asia, and Africa. Value Health Regional 2013, 2:169-170.
24. Glaser A.W., Fraser L.K., Corner J., et al. Patient-reported outcomes of cancer survivors in England 1-5 years after diagnosis: a cross-sectional survey. BMJ Open 2013, 3:e002317.
25. Hunter R.M., Isaac M., Frigiola A., et al. Lifetime costs and outcomes of repair of Tetralogy of Fallot compared to natural progression of the disease: Great Ormond Street Hospital cohort. PLoS One 2013, 8:e59734.
26. Tran B.X., Ohinmaa A., Nguyen L.T. Quality of life profile and psychometric properties of the EQ-5D-5L in HIV/AIDS patients. Health Qual Life Outcomes 2012, 10:132.